Xcout Intel
Neogene Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Neogene Therapeutics, Inc. among oncology companies — ranked by similarity to what Neogene Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Neogene Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. is a global clinical-stage biotechnology company focused on the discovery and development of engineered T cell receptor therapies targeting cancer. The company has maintained dual headquarters with a U.S. base in Santa Monica, California, and an EU base in Amsterdam, before being acquired by AstraZeneca.
Neogene Therapeutics, Inc. at a glance
Neogene Therapeutics, Inc. is an oncology company headquartered in United States. It has raised at least $125M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $110M in September 2020.
Neogene Therapeutics, Inc. funding rounds
At least $125M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $110M | 11 named | |
| Seed | $15M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Neogene Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Neogene Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biopharmaceuticals
Amolyt Pharma is a clinical-stage biotechnology company specializing in the development of therapeutic peptides for rare endocrine diseases. Acquired by AstraZeneca, the company focuses on advancing innovative treatments through clinical trials.
Biopharmaceuticals
Ambrx Biopharma was a clinical-stage biopharmaceutical company that developed antibody-drug conjugates and other targeted therapeutics using its proprietary expanded genetic code technology for site-specific protein modification. Its programs were aimed at treating cancers and served patients through partnerships and clinical development; Johnson & Johnson acquired Ambrx in 2024.
Biotherapeutics
Headquartered in South San Francisco, California, Chimera Bioengineering is a privately held biotechnology company focused on developing advanced cellular engineering technologies for cancer therapies.
Drug Discovery
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company headquartered in South San Francisco, California. It specializes in developing novel T-cell engaging therapies for the treatment of cancer.
Biopharmaceuticals
Acerta Pharma, a member of the AstraZeneca group located in Oss, Netherlands, focuses on the discovery, development, and delivery of targeted novel transformational medicines.
Similar oncology company
Avenzo Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to developing next-generation oncology treatments.
Biopharma
Arch Oncology is a clinical-stage immuno-oncology company headquartered in Brisbane, California, with an additional scientific research laboratory in St. Louis, Missouri. The company develops antibody-based cancer therapies.
Drug Discovery
VectorY Therapeutics is a fully integrated gene therapy company founded in August 2020 and based in Amsterdam, Netherlands. The company is focused on developing novel gene therapies, including clinical trials for conditions like amyotrophic lateral sclerosis (ALS).
Biopharmaceuticals
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Drug Discovery
iRegene Therapeutics is a biotechnology company headquartered in Wuhan, China, with additional facilities in Suzhou. The firm specializes in regenerative medicine and advanced cell therapies designed to redefine modern medicine.
Drug Discovery
Vivacta Biotechnology is a biopharmaceutical company headquartered in Shanghai, China, specializing in innovative biotechnology research. The company is focused on developing in vivo CAR-T therapies utilizing a targeted delivery system.
Biopharmaceuticals
ARMO BioSciences is a late-stage immuno-oncology company that develops a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Neogene Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Neogene Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →